SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology Jun 6, 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC May 1, 2018
SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis Apr 23, 2018
SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Apr 10, 2018
